Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V503 (9-valent HPV Vaccine) Immunogenicity in Chinese Males
NCT05314023Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2022
- Primary completion
- Feb 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in genital warts, human papillomavirus infection, sponsored by Merck & Co.. Started May 2022; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
genital wartshuman papillomavirus infection
Beyond the preview
Go deeper on NCT05314023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05314023.